Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod
01:32pm, Monday, 24'th May 2021
The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.
– Opinion based on the EMA's Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 –
EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology's Sotrovimab For the Early Treatment of COVID-19
08:04am, Friday, 21'st May 2021
– Opinion based on the EMA's Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 –
– Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 –
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Misses Revenue Estimates
08:17pm, Thursday, 06'th May 2021
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -473.91% and -98.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the sto
Vir Biotechnology: Not Nearly Enough
06:10pm, Wednesday, 21'st Apr 2021
VIR did well with the prophylaxis studies but failed to impress with the hospitalisation data. Upcoming EUA and EMA reviews may be catalytic.
Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study
08:50am, Wednesday, 21'st Apr 2021
Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in c
Could Vir Biotechnology Be a Millionaire Maker Stock?
06:00am, Saturday, 17'th Apr 2021
Vir is developing treatments in billion-dollar markets.
Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU
08:19am, Friday, 16'th Apr 2021
The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.
Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells
08:30am, Thursday, 08'th Apr 2021
– Growing body of evidence suggests monoclonal antibodies that target a conserved epitope have the potential to be highly effective against SARS-CoV-2 and associated known mutations –
Vir Biotechnology vs. Sorrento Therapeutics: The Wisdom of Crowds Says.
06:00am, Thursday, 08'th Apr 2021
Which stock has more potential for growth over the next year? Let's look to the stars for an answer.
Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare Conference
04:01pm, Tuesday, 06'th Apr 2021
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat
Vir Biotech's VIR-7831 Maintains Activity Against California Variant Of COVID-19 Infection
09:08am, Monday, 05'th Apr 2021
Vir Biotechnology Inc (NASDAQ: VIR) has announced new preclinical data of VIR-7831, the company's investigational monoclonal antibody (mAb) against SARS-CoV-2. The new data showed that the antibod
– Data add to growing body of pre-clinical evidence demonstrating that VIR-7831 maintains activity against all known circulating variants of concern –
Eli Lilly-Vir Bamlanivimab-VIR-7831 Combo Reduces Viral Load By 70% In Low-Risk COVID-19 Patients
09:32am, Monday, 29'th Mar 2021
Eli Lilly And Co (NYSE: LLY), Vir Biotechnology Inc (NASDAQ: VIR), and GlaxoSmithKline plc (NYSE: GSK) have announced topline data from the expanded Phase 2 BLAZE-4 trial evaluating bamlaniv
